The transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) controls differentiation of long-lived plasma cells, and almost 10% of individuals with common variable immunodeficiency (CVID) express either the C104R or A181E variants of TACI. These variants impair TACI function, and TACI-deficient mice exhibit a CVID-like disease. However, 1%-2% of normal individuals harbor the C140R or A181E TACI variants and have no outward signs of CVID, and it is not clear why TACI deficiency in this group does not cause disease. Here, we determined that TACI-deficient mice have low baseline levels of Ig in the blood but retain the ability to mutate Ig-associated genes that encode antigen-specific antibodies. The antigen-specific antibodies in TACI-deficient mice were produced in bursts and had higher avidity than those of WT animals. Moreover, mice lacking TACI were able to clear Citrobacter rodentium, a model pathogen for severe human enteritis, more rapidly than did WT mice. These findings suggest that the high prevalence of TACI deficiency in humans might reflect enhanced host defense against enteritis, which is more severe in those with acquired or inherited immunodeficiencies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347253PMC
http://dx.doi.org/10.1172/JCI74428DOI Listing

Publication Analysis

Top Keywords

taci deficiency
12
taci-deficient mice
12
taci
8
taci variants
8
antigen-specific antibodies
8
mice
5
deficiency enhances
4
enhances antibody
4
antibody avidity
4
avidity clearance
4

Similar Publications

Therapeutic agents targeting the tumor necrosis factor (TNF) superfamily cytokines B-cell activating factor (BAFF, BLyS) and/or A PRoliferation Inducing Ligand (APRIL) have demonstrated clinical effectiveness in multiple autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis, and immunoglobulin A nephropathy (IgAN). However, their clinical utility can often be limited by incomplete and/or prolonged times to clinical response and inconvenient dosing regimens, which may be improved by more potent dual inhibition of both cytokines. Povetacicept (ALPN-303; TACI vTD-Fc) is a crystallizable fragment (Fc) fusion protein of an engineered transmembrane activator and CAML interactor (TACI) domain which mediates more potent inhibitory activity than wild-type TACI-Fc or BAFF- or APRIL-specific antibodies and demonstrates superior pharmacokinetic and pharmacodynamic activity in multiple preclinical disease models.

View Article and Find Full Text PDF

B cell targeting in IgA nephropathy.

Nephrology (Carlton)

September 2024

Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.

Article Synopsis
  • The multi-hit theory explains that IgA nephropathy (IgAN) starts with galactose-deficient IgA1 (GdIgA1), leading to chronic inflammation and progressive kidney damage due to complement pathway activation and increased pressure within the glomeruli.
  • New treatments are emerging that target different stages of IgAN's pathophysiology, including drugs that regulate complement, block endothelin receptors, and inhibit glucose reabsorption in kidneys. Promising clinical trials are underway for therapies aimed at reducing GdIgA1 production by targeting specific B cells.
  • The production of nephrit
View Article and Find Full Text PDF

Current status of BAFF targeting immunotherapy in B-cell neoplasm.

Int J Clin Oncol

November 2024

Laboratory of Molecular Immunology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.

B-cell activating factor belonging to the TNF family (BAFF), also known as B-lymphocyte stimulator (BLyS), plays a crucial role in B-cell development. It has multiple receptors, including BCMA, TACI, and BAFF-R, with diverse roles in different cell types. BAFF induces B-cell proliferation and immunoglobulin secretion, and acts as a survival factor for immature, naive, and activated B cells.

View Article and Find Full Text PDF
Article Synopsis
  • Common Variable Immune Deficiency (CVID) is the most common primary immune deficiency in adults and is linked to higher rates of Non-Hodgkin Lymphomas (NHLs).
  • The review discusses changes in immune cells, genetic factors, and tissue pathology specifically related to NHLs in CVID patients.
  • Immune defects in CVID, such as reduced T cell types and alterations in B cells, along with genetic markers and signaling pathways, may contribute to increased lymphoma risk and require further research to identify potential prognostic indicators.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!